Alzheimer’s drug slows mental, functional decline in Eli Lilly trial
By
Alicia Lasek
Jan 12, 2021
Participants who took donanemab for 76 weeks showed 32% slower decline in thinking and daily function compared with those in a placebo group.
Drug that targets Alzheimer’s inflammation approved for trial by FDA
By
Alicia Lasek
Feb 09, 2021
An experimental drug meant to treat the “type 3 diabetes” that some scientists believe triggers Alzheimer’s has been approved for a late-stage clinical trial.
An Alzheimer’s reality check
By
Tim Mullaney
Nov 12, 2013
Alzheimer’s researchers — or the public relations machines breathlessly trumpeting their work — should chill out. I see so much of this type of Alzheimer’s news that it’s hard to...